MedTrace Logo

Topical Ionic Contra-Viral Therapy in Actinic Keratosis

NCT03684772 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-05-01

No results posted yet for this study

Summary

To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.

Conditions

  • Actinic Keratosis

Interventions

DRUG

ICVT Topical Gel

Digoxin and Furosemide (0.125%)

DRUG

Furosemide Topical Gel

Furosemide (0.125%)

DRUG

Digoxin Topical Gel

Digoxin (0.125%)

DRUG

Vehicle Topical Gel

Vehicle Gel

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Rissmann, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-22
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03684772 on ClinicalTrials.gov